Biomarkers of Clinical Subtype and Treatment Response in Obsessive-Compulsive Disorder
- Study HIC#:0803003626
- Last Updated:07/21/2023
This study is meant to explore
the neurobiological and psychological underpinnings of obsessive compulsive
disorder (OCD). It consists of several parts, including a phone screen followed
by some extensive interviews with staff. Research participation may then be
offered in decision making tasks or different magnetic resonance (MR) scans.
The volunteers being sought must be English speaking people, ages 18 to 70
years old, able to provide informed consent, in one of the following groups:
without OCD (controls), with subclinical OCD symptoms (e.g. Contamination
concerns) but no diagnosis, with diagnosable OCD. Economic reimbursement
averages $20 per hour. Study participation requires several visits.
Interested individuals should call 203-974-7523 or toll free 1-855-OCD-YALE (1-855-623-9253).
or email: firstname.lastname@example.org
To learn more, please see our website: ocd.yale.edu
- Age18 years - 70 years
For more information about this study, including how to volunteer, contact:
- Phone Number: 1-855-623-9253
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact email@example.com, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this study is to explore whether non-invasive measures of neural structure, chemistry and physiology in obessive compulsive disorder predict clinical response to pharmacological treatment with serotonin reuptake inhibitors and glutamate modulating agents and to explore whether non-invasive measures of neural structure, chemistry, and physiology distinguish between clinically differentiable subtypes of obsessive-compulsive disorder.
All subjects - Exclusion criteria:
a.Any contraindications to undergoing an MRI scan, including having mental implants or metal fragments in the body (contraindication to MRI, fMRI, and MRS only; subjects may still participate in ERP studies)
b.Any significant neurological or medical problem that may substantially affect CNS function, including epilepsy, stroke, thyroid disease, and poorly controlled hypertension.
c.Any unstable medical condition that may render study procedures unsafe (although all study procedures are sufficiently benign and non-invasive that this is not expected to exclude a substantial number of patients
d.Any history of significant hearing loss
e.Any history of head injury with loss of consciousness for more than 30 minutes
f.Positive urine pregnancy test
g.Active use of illicit substances
h.Active alcohol abuse
i.Primary diagnosis of a psychotic disorder
j.Primary diagnosis of pervasive developmental disorder
Subjects with OCD or OCD symptoms
2.DSM-IV diagnosis of OCD, established by a trained clinician interview and confirmed by SCID-IV administered by trained personnel
3.Y-BOCS score of at least 16 at evaluation or at some point during treatment
2.General exclusion criteria, as summarized above
Subjects with other mood and anxiety disorders
1. DSM-IV diagnosis of a mood or anxiety disorder other than OCD, established by a trained clinician interview and confirmed by a SCID-IV administered by trained personnel
1.General exclusion criteria, as summarized above
Normal control subjects
1.No significant history of major psychiatric disorder, based on clinician interview and confirmed by SCID-IV, adapted for normal controls, administered by trained personnel
2.No history of significant or prolonged psychotropic medication
1.Significant family history of OCD, major depression, psychotic disorder, bipolar disorder, or suicide
2. General exclusion criteria, as summarized above